Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures

L. E.M. de Wijs, R. F.T. Fujimoto, E. R. Andrinopoulou, T. Nijsten, D. Hijnen*, Y. Kataoka

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
32 Downloads (Pure)

Abstract

Background Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking.Objectives To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment.Methods A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time.Results We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23 center dot 8 vs. 14 center dot 8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating 'mild disease' (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan.Conclusions Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.
Original languageEnglish
Pages (from-to)555-562
Number of pages8
JournalBritish Journal of Dermatology
Volume185
Issue number3
Early online dateJun 2021
DOIs
Publication statusPublished - 1 Sept 2021

Bibliographical note

Funding Information:
ISAD Research Fellowship grant awarded to L.E.M. de Wijs. Funding sources

Funding Information:
L.E.M.d.W.: ISAD Research Fellowship grant. R.F.T.F.: research grants from AbbVie, Eli Lilly, LEO Pharma, Maruho, Otsuka and Pfizer. E.R.A. and T.E.C.N.: none. D.H.: investigator for AbbVie, Galderma, LEO Pharma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; consultancies for Incyte, Janssen, LEO Pharma, Lilly, MedImmune/AstraZeneca, Novartis, Pfizer and Regeneron/Sanofi. Y.K.: lecture honoraria from Sanofi and Sysmex; research grants from AbbVie, Eli Lilly, LEO Pharma, Maruho, Otsuka, Pfizer and Sanofi. Conflicts of interest

Publisher Copyright:
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Fingerprint

Dive into the research topics of 'Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures'. Together they form a unique fingerprint.

Cite this